Gastroenterology
ulcerative colitis to monitor their disease activity periodically at home and record their results on an app that are shared with their IBD care team. It is therefore likely that self-TDM at home may be a real possibility in the future, even if the technology is not yet available. At this present time, remote sampling coupled with established laboratory-based TDM assays provides the ideal combination of convenience for patients and high quality analytical accuracy.
Summary The treatment of IBD has made great strides in the last few decades and shows promising results for the introduction of orally administered therapies in the near future. In parallel to this, the story of TDM is also likely to evolve to accommodate the new modalities of drug delivery and meet the NHS’s expectations for more remote monitoring. However, this pending transition – and the pace at which the sector is making these changes – could counteract the benefits of implementing point-of-care TDM at this stage. Instead, non-clinic sampling combined with conventional laboratory-based TDM assays could provide more accessible and less resource- heavy sampling with greater quality assurance. This represents the first stage in the introduction of at-home TDM, potentially providing a stepping stone for self-testing in the future, and coinciding with the introduction of novel oral therapies that combined will work towards giving patients total freedom with end-to-end disease management.
References 1. Crohn’s & Colitis UK. Campaigning for early diagnosis. Accessed 23rd November, 2023.
https://crohnsandcolitis.org.uk/our-work/ campaigns/earlydiagnosis.
2. Rungoe, C., et al. 2014. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–
2011.Gut, 63(10), 1607-1616. doi:10.1136/ gutjnl-2013-305607.
3. Hazel, K., and O’Connor, A. 2020. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 11:2040622319899297. doi: 10.1177/2040622319899297.
4. Ben-Horin, S., and Chowers, Y. 2011. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 33(9):987-95. doi: 10.1111/j.1365-2036.2011.04612.
5. Kennedy, NA., et al. 2019. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 4(5):341-353. doi: 10.1016/ S2468-1253(19)30012-3.
6. Selinger C.P., et al. 2017. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a
46
www.clinicalservicesjournal.com I May 2024
Virtual Biologics Clinic for Inflammatory Bowel Disease. Inflamm Bowel Dis. 23(12):2083-2088.
7. Kumar, A., and Smith, P. J. 2023. Horizon scanning: new and future therapies in the management of inflammatory bowel
disease.eGastroenterology. 2023;1:e100012. doi: 10.1136/egastro-2023-100012.
CSJ
8. Buisson, A., et al. 2023. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol. 21(9), 2338–2346.e3.
https://doi.org/10.1016/j.cgh.2022.08.011.
9. Cronin, J., et al. 2019. The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital
setting.Ir J Med Sci 188, 821–834. https://doi. org/10.1007/s11845-018-1925-8.
10. NHS England. For colorectal: complex inflammatory bowel disease. 2014. Accessed 23rd November, 2023. https://www.england.nhs. uk/wp-content/uploads/2018/08/Colorectal- complex-inflammatory-bowel-disease-adult.pdf.
11. Kharlamova, N., et al. 2020. Drug Tolerant Anti- Drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases
Earlier.Front Immunol. 2020;11:1365. doi:10.3389/fimmu.2020.01365.
12. Chee, D., et al. 2022. Patient-led remote intracapillary pharmacoKinetic sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease. J Crohns Colitis, 16(2), 190-198. doi:10.1093/ ecco-jcc/jjab128.
13. Perry, M., et al. 2015. Infliximab and adalimumab are stable in whole blood
About the author
Graham Johnson is managing director of BIOHIT HealthCare Ltd, based in North West England. It is the UK subsidiary of BIOHIT Oyj, a Finnish biotechnology company specialising in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases.
clotted samples for seven days at room temperature. Ann Clin Biochem 52:672–4. doi:10.1177/0004563215580001.
14. NHS England. Science in healthcare: Delivering the NHS Long Term Plan. 2020. Accessed 23rd November, 2023. https://www.england.nhs. uk/wp-content/uploads/2020/03/science-in- healthcare-delivering-the-nhs-long-term-plan. pdf.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
